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0929-6646/Copyright ª 2015, ElsevierAbstract Epilepsy in children is occasionally associated with variable comorbidities although
the frequency of such comorbidity is often difficult to determine. They can be divided into
three categories: neurological, psychological, and physical comorbidities. The goal of the pre-
sent review is to discuss the reported comorbidities of epilepsy in children. The possible mech-
anisms and associated risk factorsdincluding the effect of seizure frequency and seizure
control, types of epilepsy, age of seizure onset, duration of illness, and the possible detri-
mental effect of antiepileptic drugsdwill be described.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Epilepsy is the most common childhood neurologic disorder,
affecting 0.5e1.0% of children younger than 16 years.1
Population-based studies show that 70e76% of children
with epilepsy have some types of disability or handicap
affecting their daily life and choices for the future.2,3 Epi-
lepsy in children is associated with variable comorbidities
although the frequency of such comorbidities is often
difficult to determine. This article reviews the current
knowledge of comorbidities in children with epilepsy, andhave no conflicts of interest
nt of Pediatrics, National
8, Chung-Shan South Road,
om (W.-T. Lee).
5.07.015
Taiwan LLC & Formosan Medicaldivides them into three categories: neurological, psycho-
logical, and physical comorbidities (Table 1). The possible
mechanisms and associated risk factors, including seizure
frequency and seizure control, types of epilepsy, age of
onset, duration of illness, and antiepileptic drugs (AEDs),
will be discussed.
Neurological comorbidities
Many factors may contribute to the development of
neurological morbidities in children with epilepsy,4 such as
the detrimental effects of chronic seizures on brain
development, the medications used to treat seizures, and
possibly an independent effect of the physiological distur-
bances that predispose the brain to seizures. Neurological
comorbidities in children with epilepsy are variable,
including cognitive impairment, language impairment,
migraine, and sleep problems. We will discuss these issues
in the following sections.Association. All rights reserved.
Table 1 Comorbidities of epilepsy in children.
Neurological comorbidities Psychological comorbidities Physical comorbidities
Cognitive impairment Autism spectrum disorders Bone loss
Language impairment Attention deficit/hyperactivity disorder Immunological disturbances
Migraine & headache Mood disorders (anxiety and depression) Retardation of body height growth
Sleep problems Psychosocial & familial problems Hypothyroidism
Rare: psychosis, oppositional defiant or
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The association between mental retardation and epilepsy
has been well described in the literature.5 Children with
epilepsy had high rates of grade retention and placement in
special education compared with sibling controls.6 Several
population-based prevalence studies of children with epi-
lepsy reported that intellectual disability (full-scale intel-
ligence quotient < 70) was the most common comorbidity
(30e40%).7 However, the long-term risk of learning prob-
lems exists even in those with normal IQs and well-
controlled seizures.6 Moreover, in a follow-up study the
cognitive deficits associated with childhood-onset epilepsy,
despite the duration of epilepsy, may remain consistent to
60 years of age.8
The various epilepsy syndromes of childhood differ
greatly in terms of cognitive outcome. Children with in-
fantile spasms and Dravet syndrome (severe myoclonic
epilepsy in infancy) usually have long-term cognitive and
behavioral problems.9 LennoxeGastaut syndrome is also
associated with a poor prognosis in children.10 Although
“benign epilepsy” is supposed to have better prognosis in
children, absence epilepsy has been reported to have an
increased risk for neurocognitive impairment.11 Some
studies in the past also showed that children with symp-
tomatic generalized epilepsy had a lower full-scale intelli-
gence quotient than those with idiopathic generalized
epilepsy and focal epilepsy,12 and temporal lobe epilepsy
specifically had much worse memory function than frontal
lobe epilepsy and childhood absence epilepsy.13
Many factors of childhood epilepsy may contribute to the
development of cognitive impairment in children. Children
with epilepsy and abnormal electroencephalograms scored
lower than those with normal electroencephalograms on
reading and spelling measures, even with comparable IQs.6
Young age at onset, symptomatic cause, epileptic enceph-
alopathy, and continued treatment of AEDs were also re-
ported to be independently associated with cognitive
outcome.14,15 Older AEDs (prior to1990), such as pheno-
barbital, can produce greater cognitive impairment. How-
ever, carbamazepine, phenytoin, and valproic acid (VPA)
are comparable in their cognitive effect.16 Among the new
AEDs, topiramate is reported to be significantly associated
with memory and cognitive problems,17 and the frequency
of side effects in cognition is dose-related.18 Oxcarbaze-
pine,19 lamotrigine,20 and levetiracetam21 are found to
have no or few adverse effects on cognition. Carefulselection of AEDs, avoiding polytherapy, slow titration, and
using the lowest effective AED dose are reported to
decrease the cognitive side effects of AEDs in children with
epilepsy.16
Language impairment
The language impairment in children with epilepsy may
arise from a number of factors, including underlying
neuropathology, the impact of seizures on the developing
brain, the development of cognition, and the severity of
epilepsy in children.22 The occurrence of speech disorders
may be as high as 27.5% in children with epilepsy.5
Compared with their siblings, children with epilepsy may
also have significantly lower language scores in word
knowledge, category fluency, and response to commands of
increasing length and complexity,23 especially in those with
an earlier age of onset.
Some epileptic syndromes have been well documented
in association with language impairment. The Landau-
eKleffner syndrome (LKS) and the epilepsy with continuous
spike waves during slow-wave sleep (CSWS) share several
common features: both are age-related, first appear in
childhood, and are characterized by mild epilepsy associ-
ated with severe neuropsychological dysfunction. Language
disorders in LKS mainly involve comprehension with pres-
ervation of nonverbal intellectual functions.24 Children
with LKS have a variable prognosis. Some regain speech and
others have permanent speech impairment.9 By contrast,
language disorders associated with CSWS are predominant
in the areas of lexical and grammatical judgment, whereas
comprehension is spared. Patients in remission and those in
an active phase of CSWS have the same language impair-
ment profiles.25 Children with benign epilepsy with cen-
trotemporal spikes, which is now recognized as lying on a
spectrum with the LKS, may also have the comorbidity of
mild language impairment, mainly with oromotor perfor-
mance and auditory discrimination, including poor tongue
movements and articulation, and worse performance on
dichotic listening.26
Migraine
The links between epilepsy and migraine have long been
known but have been incompletely understood. Both are
believed to result from brain hyperexcitability, and the
therapeutic agents effective for each disorder may
Comorbidity of children with epilepsy 1033overlap.27 Migraine and epilepsy are highly comorbid and
individuals with each disorder are more than twice as likely
to have the other.28 Stevenson29 reported a higher preva-
lence of migraine in children with epilepsy (14.7%) than in
the general population (2.7e11%). Children with epilepsy
had a 4.5-fold increased risk of developing migraine head-
ache than tension-type headache.30 The headaches usually
start in the same year or after the diagnosis of epilepsy and
occur mostly in children older than 10 years with idiopathic
epilepsy.31 Specifically, a strong association of epilepsy
with rolandic paroxysms and migraine in children has been
reported.32 A controlled study revealed that migraine was
more prevalent in children with benign epilepsy with cen-
trotemporal spikes and juvenile myoclonic epilepsy.33
Sleep problems
It has been reported that children with epilepsy have
significantly more sleep problems,34 including parasomnias,
parent/child interaction during the night, sleep fragmen-
tation, daytime drowsiness, and bedtime difficulties.35
Children with seizures also have more sleep problems
than seizure-free children.35 Evidence suggests that both
the occurrence of seizures and AEDs are associated with
significant sleep disruption. Persistent daytime drowsiness
in children with epilepsy is not always due to the side ef-
fects of AEDs and may arise from sleep fragmentation.36
Children with epilepsy have longer stage 1 sleep per-
centage and latency to rapid eye movement (REM) sleep
compared with controls.37,38 It is also found that REM la-
tency, length of apnea, and periodic leg movement in
children with epilepsy correlated with depression, inat-
tentiveness and hyperactivity, and/or oppositional
behavior.37 It is reported that continuous positive airway
pressure treatment of obstructive sleep apnea, which is a
specific type of sleep disorder, and more comorbid in chil-
dren (20%) than in adults (10%) with epilepsy, improves
seizure control, cognitive performance, and quality of
life.38 Moreover, a particular pattern of association has
been found between nocturnal frontal lobe epilepsy and
non-REM arousal parasomnias, the latter being found in the
personal or family history of up to one-third of children
with nocturnal frontal lobe epilepsy.38
Psychiatric comorbidities
Psychiatric comorbidities are common in children with ep-
ilepsy, and constitute a significant burden to the children
and their families. Some studies have shown that a psy-
chiatric disorder can emerge in children early in the course
of their illness39 or even prior to the onset of seizures.40
The most common psychiatric disorders among children
who have epilepsy include attention deficit/hyperactivity
disorder (ADHD), and depressive and anxiety disorders.
Although infrequent, psychosis, oppositional defiant, and
tic disorders may occur in children who have epilepsy.41,42
Autism spectrum disorders
It is well documented that children with autism spectrum
disorder (ASD) have an increased prevalence of seizures,which is estimated to be w20e25% of the whole spec-
trum.43 However, the prevalence of ASD in children with
epilepsy is rarely reported, and varies depending on age,
types of epilepsy, and method of evaluation. In a
questionnaire-based study, as high as 32% of children fit the
criteria of autism screening questionnaires for having
ASD.44 Most of them had not been previously diagnosed.
The children identified as being at risk of having ASD have
right temporal lobe lesions,45 worse behavior, daytime
sleepiness, and a younger mean age of seizure onset, atw2
years of age.44 The high correlation between ASD, neuro-
logic dysfunction, and epilepsy suggests an underlying en-
cephalopathy presenting with a combination of neurologic
abnormalities, including clinical epileptiform activity.46
ADHD
The prevalence of ADHD is estimated to be between 12%
and 39% in children with epilepsy, and is much higher than
3e7% in the general population of children.47 ADHD is
significantly more prevalent in children with new-onset
epilepsy compared to healthy controls (31% vs. 6%,
respectively), and the predominant ADHD type is the inat-
tentive type.48 A population-based study using data from
the Taiwan National Health Insurance Research Database
revealed a 2.54-fold increased risk of subsequent ADHD in
children with epilepsy compared to normal controls, and
the age-specific risks increased with age, at 2.26-, 3.53-,
and 5.30-fold for patients aged 0e6 years, 6e12 years, and
12e18 years, respectively.49
Symptoms of ADHD are more common in some specific
types of epilepsies, such as frontal lobe epilepsy, childhood
absence epilepsy, and rolandic epilepsy, and may antedate
seizure onset in a significant proportion of cases.50,51 In a
study of Taiwanese children with epilepsy, a history of
developmental delay predicted ADHD-related symptoms
and an earlier onset of epilepsy predicted inattention and
hyperactivity/impulsivity.52
Mood disorders
Mood disorders had been reported in 12e26% of children
with epilepsy.53 Emotional disorders can be found in 16.7%
of children with complicated epilepsy and in 16% of those
with uncomplicated epilepsy compared with 4.2% in the
general population.54 Ott et al55 reported mood disorders in
12% and 13% of children with complex partial seizures and
childhood absence epilepsy, respectively.
In general, children with epilepsy display more inter-
nalizing problems (withdrawal, somatic complaints, anxi-
ety, and depression symptoms) than they do externalizing
problems such as acting out and conduct problems.23,55 The
higher ratings on the somatization and emotional with-
drawal were found among children with poor seizure
control.56
In addition to ADHD, the most common psychiatric dis-
orders among children with epilepsy are depressive and
anxiety disorders.41 Seizure frequency,57 AED poly-
therapy,57,58 types of AEDs,59,60 and duration of illness57,58
are all related to the development of these comorbid-
ities. The depression, which is more comorbid in those
Table 2 Relationship between physical comorbidities and
medical treatment of antiepileptic drugs (AEDs) in children
with epilepsy.
Comorbidities Type of AEDs Refs








Weight gain VPA,a GBP, PGB, VGB 87,89,90
Weight loss TPM, FBM, ZNS 89
Dyslipidemia CBZ, PB 94e96
Carnitine deficiency VPA,a OXC. CBZ, PHT, PB 98e100
CBZ Z carbamazepine; FBM Z felbamate; GBP Z gabapentin;
LMT Z lamotrigine; OXC Z oxcarbazepine;
PB Z phenobarbital; PGB Z pregabalin; PHT Z phenytoin;
TPM Z topiramate; VGB Z vigabatrin; VPA Z valproic acid;
ZNS Z zonisamide.
a More significant than the other drugs.
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the children whose medication is discontinued but persists
in those maintained on this medication. The brain regions
commonly involved in various types of epilepsies, such as
the hippocampus and amygdala in temporal lobe epilepsy
and subcortical nuclei in idiopathic generalized epilepsies,
are important components of current models of depres-
sion.60,61 One study also found a sex effect with more
depression in adolescent girls with epilepsy,62 and another
study noted an age effect with higher depression rates in
adolescents.57 In contrast to depression with a trend in
older children with epilepsy, anxiety is more comorbid in
younger children (< 12 years old) with epilepsy.53,57
Certain psychiatric disorders, including primary mood
disorders, increase the risk for suicide in adults with epi-
lepsy.63 Only a few studies, however, examined suicidality
in children with epilepsy.55,59 Ott et al55 reported suicidal
ideation in 17% and 18% and suicidal intent in 8% and 11% of
complex partial seizure and childhood absence epilepsy,
respectively, but these rates were not significantly higher
than those in normal children (9% ideation, 1% intent).
Brent et al59 found suicidal ideation in 40% of children with
epilepsy treated with phenobarbital, compared with only
4% of children with epilepsy treated with carbamazepine.
Among the new AEDs, topiramate and lamotrigine already
list suicidality on their package inserts but lack the evi-
dence of clinical trials in pediatric patients.64
Other neuropsychiatric problems
To compare with healthy children, oppositional defiant
(13% vs. 2%) and tic disorders (9.4% vs. 2%) are more com-
mon but considerably less prevalent.41 A significantly
increased rate of tic disorders is evident among children
with localization-related epilepsy, and a significantly
increased rate of conduct disorders in children with primary
generalized epilepsy.41
The incidence of psychosis appears to be rare in children
who have epilepsy. Ictal and postictal psychosis can occur
but are rare.42 A postictal psychotic episode may occur
after a prolonged seizure or a cluster of seizures. The
psychotic episode can last several days and typically re-
solves spontaneously. If psychotic symptoms occur during
seizures, they typically are stereotyped, and children may
be unable to recall the content of the hallucination. This
pattern is in contrast to children who have psychosis, who
generally are able to describe the hallucination, which can
vary from episode to episode. Changes in AEDs always
should be considered when evaluating psychosis in children
who have epilepsy. AED-induced psychotic reactions have
been reported with the following medications: phenytoin,
topiramate, lamotrigine, ethosuximide, vigabatrin, zonisa-
mide, and felbamate.42
Psychosocial and familial problems
Epilepsy is a chronic disorder, affecting children and their
families across the environments in which children func-
tion, specifically home and school,65 and increasing
adjustment reactions, and familial and social stress.66 They
are also at increased risk for poor health-related quality oflife even in the absence of active seizures.67 Depression or
psychological distress is the strongest predictors of their
quality of life.68 Also, family factors, especially those
related to the quality of parentechild relationship, appear
to be strong predictors of the quality of life among these
children and their family.69 Moreover, a study of psycho-
logical health about the family members of patients
revealed an increased risk of psychiatric problems among
the mothers of the chronically epileptic children, but not
fathers and siblings.39
Physical comorbidities
Children with epilepsy may experience physical comorbid
conditions caused by the disease itself or adverse effects of
treatment. Most well-known adverse effects of AED treat-
ment, including allergic reaction, cytopenia, electrolyte
imbalance, and renal or hepatic impairment, are notable
and probably reversible after ceasing AED use. However,
some physical comorbidities related to AEDs, including
disturbances of hormonal balance, may potentially have a
long-term impact on the medical health and quality of life
of the children with epilepsy. Table 2 summarizes the re-
ported physical comorbidities caused by specific AEDs in
children with epilepsy.
Bone loss
Recent studies revealed that abnormal bone mineral den-
sity (BMD) was found in 58.3% of patients with epilepsy,
with osteopenia and osteoporosis in 75% and 25%, respec-
tively.70 Patients with symptomatic epilepsy, severe mental
retardation, lack of autonomous gait, and less physical
activity significantly correlated with abnormal BMD,70 and
boys with more chronic epilepsy ( 6 years) had the lowest
BMD.71 AEDs and the duration of treatmentdrather than
the number of drugsdseem to play a significant role in
abnormal BMD. Topiramate as adjunctive therapy and, to a
Comorbidity of children with epilepsy 1035lesser extent, VPA, phenobarbital, and lamotrigine also
correlated with lower BMD.70 Although > 50% of children
and adolescents with epilepsy have low serum vitamin D
levels, this finding does not correlate with BMD.72Immunological disturbances
Immunological disturbances have been found in children
with epilepsy prior to and after AED treatment. Immune
mechanisms may be involved in the pathogenesis of some
epilepsy syndromes in children, including West syndrome,
LennoxeGastaut syndrome, and LKS, which may benefit
from treatment with intravenous immunoglobulin (Ig).73 A
Dutch study also found that serum levels of IgA, IgG1, IgG2,
and IgG4 in children with newly diagnosed epilepsy were
increased prior to the treatment, and that these distur-
bances were independent from etiology and the types of
epilepsy syndromes.74 It indicates that epileptic seizures
may affect the immune system indirectly. Treatment with
AEDs, including phenytoin,75,76 carbamazepine,76,77 and
VPA,77 had also been shown to change the humoral and
cellular immunity.Body height and growth hormone deficiency
Retardation of body height growth in children with epilepsy
has been described in many studies.78 Children with epi-
lepsy have reduced mean height percentile compared with
controls, which was negatively correlated with the types of
epilepsy, the duration of epilepsy, and the degree of
seizure control.78,79 Although basal growth hormone levels
showed no significant change, post provocation growth
hormone and insulin growth factor-1 levels were signifi-
cantly lower in patients with epilepsy.78 By contrast, the
effect of AEDs on body height or growth hormone of chil-
dren with epilepsy is controversial. A reduction in growth
hormone response was found in both treated and untreated
children with epilepsy, whereas treatment with phenytoin
and VPA resulted in a significant increase and decrease,
respectively, in growth hormone release after different
stimulatory tests.80 However, other studies showed that
VPA, carbamazepine, or oxcarbazepine had no significant
difference in affecting linear growth or growth hormone of
these children.78Hypothyroidism
Long-term AED therapy has been reported to cause sub-
clinical hypothyroidism in children with epilepsy.81,82 Eiris-
Punal et al81 found that subclinical hypothyroidism was
more common in children receiving VPA (26%) and carba-
mazepine (8.2%) treatment compared to normal controls
(3.6%). Hypothyroidism was also reported to be more
evident if carbamazepine was given with VPA. However,
thyroid-stimulating hormone and thyrotropin-releasing
hormone levels were not affected, suggesting that AEDs
did not affect hypothalamic function in these children.82Polycystic ovary syndrome and sexual maturation
The polycystic ovary syndrome (PCOS) is an important
physical concern in female adolescents with epilepsy.83 In
PCOS, anovulatory cycles are associated with more
frequent seizures and migraine attacks.83 An association
between PCOS and AED treatment has not always been
demonstrated.84 The view that AEDs, in particular VPA, play
a role in the development of PCOS is based on experience
from several other series, clinical improvement after
switching from VPA to lamotrigine, and recent animal
data.85 The mechanism by which VPA may precipitate PCOS
has not been entirely elucidated, and VPA-mediated
changes in androgen metabolism may play a key role.79,86
Although AEDs are presumed to be associated with PCOS,
current evidence shows that AEDs do not seem to have any
adverse effects on pubertal development79 and sexual
maturation87 in girls with epilepsy.
Epilepsy itself may also be related to PCOS via epilep-
tiform discharges disrupting normal hypothalamic func-
tion.88 Female teens with epilepsy usually have a high
prevalence of PCOS, independent of the types of AEDs or
the characteristics of the epilepsy.79Body weight changes
Many AEDs are associated with substantial weight changes.
Felbamate, topiramate, and zonisamide may cause weight
loss, whereas VPA, gabapentin, pregabalin, and vigabatrind
and, possibly, carbamazepinedare related to weight gain.89
VPA is the most recognized one causing weight gain,87,90 and
the relationship seems to be sex-specific in adolescents.90
Studies have reported the association of obesity and hyper-
insulinemia with VPA-related PCOS and hyperandrogenism in
puberty and postpuberty girls with epilepsy.86 In prepubertal
children with epilepsy, the VPA-related weight gain may be
associated with the increase in serum ghrelin, a major hor-
mone regulating the energy balance of the body, in the early
treatment period,91 but there is no more significance of
excessiveweight gain in the long-term follow-up of VPA use.92
Nevertheless, a recent study showed that obesity is also a
common comorbidity in children with newly diagnosed
epilepsy prior to treatment, and correlates with increasing
age, idiopathic etiology, and absence of concomitant
medication.93Dyslipidemia
Previously published studies on the effect of AEDs on serum
lipid profiles have mostly comprised adults or adults and
children together.94 Studies in children alone were limited,
and most showed the changes to be transient and revers-
ible.95 Recently, it was reported that total cholesterol,
high-density lipoprotein cholesterol, and low-density lipo-
protein cholesterol levels were all increased in children on
long-term therapy with carbamazepine or phenobarbital,
whereas long-term VPA therapy decreased values of these
lipid profiles.96
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Carnitine deficiency causes clinical signs and symptoms
such as gastrointestinal dysmotility, manifesting by vomit-
ing, delayed gastric emptying, and constipation, and other
symptoms such as muscle weakness, hypotonia, cardiomy-
opathy, and even encephalopathy.97 Hypocarnitinemia
have been reported in pediatric patients receiving AEDs,
especially during long-term or high-dose therapy, including
oxcarbazepine. carbamazepine, phenytoin, phenobarbital,
and particularly VPA.98e100 Some epileptic children taking
VPA may have depleted carnitine stores, especially in their
muscles, despite having normal serum carnitine levels.99Perspective strategies and recommendations
Comorbid conditions are variable and common in children
with epilepsy, and often more disabling than the seizures
themselves. Management strategies focus not only on con-
trolling seizures, but also on early diagnosis and therapy of
comorbid conditions. Therefore, identification of such dif-
ficulties should be an integral part of management in
childhood epilepsy. Most important of all, it is recom-
mended that clinicians screen and assess the possible
neurological and psychological comorbidities both in chil-
dren with newly diagnosed epilepsy and those with regular
follow-up after treatment. Some of these difficulties may
occur as early as in newly diagnosed epilepsy prior to
treatment and in children with controlled epilepsy. Many
factors may contribute to the development of physical
morbidities in children with epilepsy, such as the detri-
mental effects of chronic seizures and AEDs. When a
physical comorbidity is suspected to result from a specific
medication (Table 2), alternatives should be considered.
Because of a significant impact of childhood epilepsy on
children and their families, further work should also focus
on the educational strategies of psychosocial support to
decrease the adjustment problems, and familial and social
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